Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A

BACKGROUND: Emicizumab is a bispecific monoclonal antibody developed for routine prophylaxis of bleeding in people with hemophilia A (PwHA). This work characterizes the pharmacokinetics of emicizumab in adult and pediatric PwHA, identifies factors contributing to its between-person variabilities, co...

Descripción completa

Detalles Bibliográficos
Autores principales: Retout, Sylvie, Schmitt, Christophe, Petry, Claire, Mercier, François, Frey, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717049/
https://www.ncbi.nlm.nih.gov/pubmed/32504271
http://dx.doi.org/10.1007/s40262-020-00904-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717049/
https://www.ncbi.nlm.nih.gov/pubmed/32504271
http://dx.doi.org/10.1007/s40262-020-00904-z

Ejemplares similares